Resiquimod (R-848)

For research use only. Not for use in humans.

目录号:S8133 别名: S28463 中文名称:雷西莫特, 瑞喹莫德

Resiquimod (R-848) Chemical Structure

CAS No. 144875-48-9

Resiquimod (R-848, S28463)是一种免疫反应调节剂,用作有效的TLR 7/TLR 8激动剂并可诱导如 TNF-αIL-6IFN-α 等细胞因子的上调。Resiquimod 可减少 hepatitis C virus (HCV)感染。Phase 2。

规格 价格 库存 购买数量  
RMB 794.43 现货
RMB 1777.23 现货
RMB 5298.93 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Resiquimod (R-848)发表文献8篇:

产品安全说明书

TLR抑制剂选择性比较

生物活性

产品描述 Resiquimod (R-848, S28463)是一种免疫反应调节剂,用作有效的TLR 7/TLR 8激动剂并可诱导如 TNF-αIL-6IFN-α 等细胞因子的上调。Resiquimod 可减少 hepatitis C virus (HCV)感染。Phase 2。
靶点
TLR7 [1] TLR8 [1]
体外研究

Resiquimod激活免疫细胞,并通过Toll-样受体7(TLR7)-MyD88-依赖性信号通路诱导野生型脾细胞的增殖。[1] Resiquimod也会调节树突细胞以增加巨细胞病毒-和HIV-1-特异性T细胞应答。[2] Resiquimod诱导髓源性抑制细胞分化为巨噬细胞和树突细胞,并且可以通过减少免疫抑制的MDSCs提高癌症免疫治疗效果。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PBMC MkDhSpVv[3Srb36gZZN{[Xl? NHnEdVM{OCCwTR?= MlHmNVghcHK| NHrSblNKdmS3Y4Tpc44hd2ZidInw[UAyKEmITjDz[YNz\XSrb36gbY4hcHWvYX6gVGJOSyCjdDCzNEBvVSCjZoTldkAyQCCqcoOgZpkhTUyLU1GsJGFkfGm4aYT5QVAvODBzMkZOwG0v NXHad3o{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCyN|I5OjRpPkKwNlMzQDJ2PD;hQi=>
PBMC MWjGeY5kfGmxbjDhd5NigQ>? MmmyNVAhdk1? M4\2O|E5KGi{cx?= MX3JcoR2[3Srb36gc4YhfHmyZTCxJGlHViC|ZXPy[ZRqd25iaX6gbJVu[W5iUFLNR{BifCBzMDDuUUBi\nSncjCxPEBpenNiYomgSWxKW0FuIFHjeIl3cXS7PECuNFAyOjYQvF2u M2XtZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMkOyPFI1Lz5{MEKzNlgzPDxxYU6=
PBMC MUfGeY5kfGmxbjDhd5NigQ>? NILaPYIyODBibl2= NYnNZVduOThiaILz MonMTY5lfWO2aX;uJI9nKHS7cHWgNUBKTk5ic3XjdoV1cW:wIHnuJIh2dWGwIGDCUWMh[XRiMUCwJI5OKGGodHXyJFE5KGi{czDifUBGVEmVQTygRYN1cX[rdIm9NE4xODV4Md88UU4> MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODJ|MkiyOEc,OjB{M{K4NlQ9N2F-
PBMC MWDGeY5kfGmxbjDhd5NigQ>? NHLXWpM{ODBibl2= MoTJNVghcHK| M4rZOmlv\HWldHnvckBw\iC2eYDlJFEhUU[QIIPlZ5JmfGmxbjDpckBpfW2jbjDQRm1EKGG2IEOwNEBvVSCjZoTldkAyQCCqcoOgZpkhTUyLU1GsJGFkfGm4aYT5QVAvODB5MkdOwG0v MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODJ|MkiyOEc,OjB{M{K4NlQ9N2F-
PBMC NYPad|JJTnWwY4Tpc44h[XO|YYm= MX2xNFAxKG6P NHzG[48yQCCqcoO= NVLXXoFWUW6mdXP0bY9vKG:oIIT5dIUhOSCLRl6gd4VkemW2aX;uJIlvKGi3bXHuJHBDVUNiYYSgNVAxOCCwTTDh[pRmeiBzODDodpMh[nliRVzJV2EtKEGldHn2bZR6RTBwMEC3O|XPxE1w MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODJ|MkiyOEc,OjB{M{K4NlQ9N2F-
Huh7 M37NfmFvfGm4aYLhcEBie3OjeR?= MVq0PEBpenN? MYjBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIR3YhcW6oZXP0[YQhcHWvYX6gTJVpPyC{ZYDsbYNwdiClZXzsd{B1emWjdHXkJIZweiB2ODDodpMhf2m2aDDkdpVoNWmwZIXj[YQhdWm6ZXSg[I9vd3JiaIXtZY4hWEKPQzDzeZBmem6jdHHueJMh[XO|ZYPz[YQh[XNidnnyZYwhdGW4ZXzzJIJ6KGy3Y3nm[ZJie2ViYYPzZZktKEWFNUC9NE4xOjUQvF2u NG\MW5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W0PFQ6Pyd-MUe1OFg1QTd:L3G+
Huh7 M3W2cmFvfGm4aYLhcEBie3OjeR?= NWHwWYNTPDhiaILz NXW5V3BKSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEOYIHnu[oVkfGWmIHj1cYFvKEi3aEegdoVxdGmlb36gZ4VtdHNidILlZZRm\CCob4KgOFghcHK|IIfpeIgh\HK3Zz3pcoR2[2WmIIPpcodt\SCmb37vdkBpfW2jbjDQRm1EKHO3cHXycoF1[W62czDhd5Nme3OnZDDhd{B3cXKjbDDs[ZZmdHNiYomgcJVkcW[ncnHz[UBie3OjeTygSWM2OD1yLkCyOlXPxE1w M4PtXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUS4OFk4Lz5zN{W0PFQ6PzxxYU6=
PBMC M4nS[GZ2dmO2aX;uJIF{e2G7 MYOyOEBpenN? MUjJcoR2[3Srb36gc4YhUU[QYXzwbIEz[SCuZY\lcEBqdiCqdX3hckBRSk2FIHHzd4V{e2WmIHHzJIRzfWdibHX2[Ywh[2G3c3nu[{Bu[XirbXHsJIN6fG:taX7lJIlv\HWldHnvckBi\nSncjCyOEBpenNicnXsZZRqfmVidH:gZ49vfHKxbDygRYN1cX[rdIm9NE4y|ryPLh?= NFfKNFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W0PFQ6Pyd-MUe1OFg1QTd:L3G+
PBMC MVvGeY5kfGmxbjDhd5NigQ>? MUOyOEBpenN? MnXVWI95cWNiaX7keYN1cW:wIH;mJGlNOS2kZYThJIxmfmWuIHnuJIh2dWGwIGDCUWMh[XO|ZYPz[YQh[XNiZIL1[{Bt\X[nbDDjZZV{cW6pIH3hfIlu[WxiY4n0c4tqdmViaX7keYN1cW:wIHHmeIVzKDJ2IHjyd{Bz\WyjdHn2[UB1dyClb370do9tNCCDY4Tpeol1gT1zzszNMi=> MlzpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3NEi0PVcoRjF5NUS4OFk4RC:jPh?=
PBMC M{TYZWZ2dmO2aX;uJIF{e2G7 NUHPO4FCOjRiaILz NXTYRXd4XG:6aXOgbY5lfWO2aX;uJI9nKEmONjDs[ZZmdCCrbjDoeY1idiCSQl3DJIF{e2W|c3XkJIF{KGS{dXegcIV3\WxiY3H1d4lv\yCvYYjpcYFtKGO7dH;rbY5mKGmwZIXjeIlwdiCjZoTldkAzPCCqcoOgdoVt[XSrdnWgeI8h[2:wdILvcEwhSWO2aY\peJk:Oc7:TT6= M2P1Z|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUS4OFk4Lz5zN{W0PFQ6PzxxYU6=
PBMC M{G3fmZ2dmO2aX;uJIF{e2G7 NXH1S2hbOjRiaILz NX3pfYE4XG:6aXOgbY5lfWO2aX;uJI9nKFSQRnHsdIhiKGyndnXsJIlvKGi3bXHuJHBDVUNiYYPz[ZN{\WRiYYOg[JJ2\yCuZY\lcEBk[XW|aX7nJI1igGmvYXygZ5l1d2urbnWgbY5lfWO2aX;uJIFnfGW{IEK0JIhzeyC{ZXzheIl3\SC2bzDjc451em:uLDDBZ5Rqfmm2eU2x{txONg>? M2K1elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUS4OFk4Lz5zN{W0PFQ6PzxxYU6=
HEK293 MmnTSpVv[3Srb36gZZN{[Xl? MoLjOkBpenN? MnTwRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDUUHI4KGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[W[2ZYKgOkBpenNiYomgUmZs[XCyYVKtcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCPRVO9NE4y|ryPLh?= MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF2M{SyOUc,OzBzNEO0NlU9N2F-
HEK293 MWTGeY5kfGmxbjDhd5NigQ>? MnPxRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDUUHI4KGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[2:neIDy[ZN{cW6pIIDObWZ1gTJvU1XBVEBz\XCxcoTldkBjgSC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR|UxRTBwMk[wNe69VS5? NYe3W5d{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCyN|I5OjRpPkKwNlMzQDJ2PD;hQi=>
HEK293 NHGyOWVHfW6ldHnvckBie3OjeR?= NEjxR5k3KGi{cx?= NInQV|RC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHRNWjhiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjZoTldkA3KGi{czDifUBPTmujcIDhRk1tfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIF3FR|0xNjQQvF2u Mn3oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzNEO0NlUoRjNyMUSzOFI2RC:jPh?=
HEK NWHHUWJ2TnWwY4Tpc44h[XO|YYm= MWO4JJRwKDF{IHjydy=> MWDB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGTMVlch\XiycnXzd4VlKGmwIFjFT{Bk\WyuczDh[pRmeiB6IITvJFEzKGi{czDifUBPTmujcIDhRk9UTUGSIILldI9zfGW{IHflcoUh[XO|YYmsJGVEPTB;MT6zOO69VS5? NX\KTmxkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxOVIxPDZpPkK5NVUzODR4PD;hQi=>
HEK MXzGeY5kfGmxbjDhd5NigQ>? M4ex[lI1KGi{cx?= MUTB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGTMVlchfHKjboPm[YN1\WRiaX6gTGVMKGOnbHzzJIF{e2W|c3XkJIF{KE6Ia3HwdIFDKGmwZIXjeIlwdiCjZoTldkAzPCCqcoOgZpkhe3CnY3nmbYMhe2WlcnX0[YQh[WytYXzpcoUheGixc4DoZZRie2ViZ3Xu[UBie3OjeTygSWM2OD1zLkVOwG0v M3j0S|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEO3PFEyLz5{MkizO|gyOTxxYU6=
HEK293 NGP1dnZHfW6ldHnvckBie3OjeR?= M1\FOVI1KGi{cx?= MUjB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGTMVk04KGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JHNGSVBicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1zLkZOwG0v M2fRNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{izOFc2Lz5{NEO4N|Q4PTxxYU6=
HEK293 NXG4b4NOTnWwY4Tpc44h[XO|YYm= MmLlOkBpenN? NUTKS|I{SWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBVVFJ6IHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiaX7jeYJifGWmIH\vdkA3KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:PM7:TT6= NGXjOJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{K3NFAzQSd-MkeyO|AxOjl:L3G+
HEK293 Mmq0SpVv[3Srb36gZZN{[Xl? Moe2NlQhcHK| M3\KZmFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gWGxTNThiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjZoTldkAzPCCqcoOgZpkhW0WDUDDy[ZBwenSncjDn[Y5mKGG|c3H5MEBGSzVyPUSuOe69VS5? NXXEW4E{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPFM1PzVpPkK0N|g{PDd3PD;hQi=>
HEK M3;BbWZ2dmO2aX;uJIF{e2G7 MUK4JJRwKDF{IHjydy=> MWPB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGTMVlgh\XiycnXzd4VlKGmwIFjFT{Bk\WyuczDh[pRmeiB6IITvJFEzKGi{czDifUBPTmujcIDhRk9UTUGSIILldI9zfGW{IHflcoUh[XO|YYmsJGVEPTB;Nj6xN:69VS5? NHTxSog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG1NlA1Pid-MkmxOVIxPDZ:L3G+
HEK MlzOSpVv[3Srb36gZZN{[Xl? NEjkOXMzPCCqcoO= NYKxcFNqSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBVVFJ6IITyZY5{\mWldHXkJIlvKEiHSzDj[YxteyCjc4Pld5Nm\CCjczDOSotieHCjQjDpcoR2[3Srb36gZYZ1\XJiMkSgbJJ{KGK7IIPw[YNq\mmlIIPlZ5JmfGWmIHHsb4FtcW6nIIDoc5NxcGG2YYPlJIdmdmViYYPzZZktKEWFNUC9Ok41|ryPLh?= M3nvblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEO3PFEyLz5{MkizO|gyOTxxYU6=
PBMC NG\ZRYJHfW6ldHnvckBie3OjeR?= M1vvbVI1KGi{cx?= M1HCT2lv[3KnYYPlJIlvKEmITnHsdIhiKGyndnXsJIlvKGi3bXHuJHBDVUNiYX\0[ZIhOjRiaILzJJJmdGG2aY\lJJRwKGOxboTyc4w> NF3BcVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W0PFQ6Pyd-MUe1OFg1QTd:L3G+
PBMC M3H6UGZ2dmO2aX;uJIF{e2G7 MYqyOEBpenN? M4POfGlv[3KnYYPlJIlvKDJpLEWnMY9tcWexYXTlcplt[XSnIIP5cpRp[XOnIHzleoVtKGmwIHj1cYFvKFCETVOgZYZ1\XJiMkSgbJJ{KHKnbHH0bZZmKHSxIHPvcpRzd2x? M4PoV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUS4OFk4Lz5zN{W0PFQ6PzxxYU6=
PBMC NFjIWVdVd3irY3n0fUBie3OjeR?= NIHKRmczPCCqcoO= M{\RWHRwgGmlaYT5JIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIFnMOkBt\X[nbDDpckBpfW2jbjDQRm1EKGGodHXyJFI1KGi{czDy[YxifGm4ZTD0c{Bkd262cn;s Mnr0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3NEi0PVcoRjF5NUS4OFk4RC:jPh?=
Huh7 NFP3S25CdnSrdnnyZYwh[XO|YYm= M1Ta[|I1KGi{cx?= NHXFbIRCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJS1ZiaX7m[YN1\WRiaIXtZY4hUHWqNzDy[ZBtcWOxbjDj[YxteyC2cnXheIVlKG[xcjCyOEBpenNid3n0bEBlenWpLXnu[JVk\WRiaIXtZY4hWEKPQzDzeZBmem6jdHHueJMh[XO|ZYPz[YQh[XNidnnyZYwhdGW4ZXzzJIJ6KGy3Y3nm[ZJie2ViYYPzZZk> NIXiSog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W0PFQ6Pyd-MUe1OFg1QTd:L3G+
Huh7 M3HTWWFvfGm4aYLhcEBie3OjeR?= MVvBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIR3YhcW6oZXP0[YQhcHWvYX6gTJVpPyC{ZYDsbYNwdiClZXzsd{B1emWjdHXkJJdqfGhiZIL1[{1qdmS3Y3XkJIh2dWGwIGDCUWMhe3WyZYLuZZRidnS|IHHzd4V{e2WmIHHzJJZqemGuIHzleoVteyCkeTDseYNq\mW{YYPlJIF{e2G7 NXPWVm9rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OFg1QTdpPkG3OVQ5PDl5PD;hQi=>
PBMC NHvGfpBHfW6ldHnvckBie3OjeR?= NGmzcmgzOi53IIXN M3nFdVI1KGi{cx?= MYnB[49vcXO2IHHjeIl3cXS7IHH0JHRNWjdxVFzSPEBqdiCqdX3hckBRSk2FIHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCWTl[tZYxxcGFicILv[JVkfGmxbjDheEAzOi53IIXNJIFnfGW{IEK0JIhzeyCkeTDmcI94KGO7dH;t[ZRzcWNiYX7hcJl{cXN? M1LJPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{izOFc2Lz5{NEO4N|Q4PTxxYU6=
PBMC NHq0V5dKdW23bn;tc4R2dGG2b4L5JIF{e2G7 MmnrNVYhfU1? M3XHXFI1KGi{cx?= NX3EUHZJUW2vdX7vcY9lfWyjdH;yfUBi[3Srdnn0fUBqdiCqdX3hckBRSk2FIHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCLTD22JJNm[3KndHnvckBifCBzNjD1UUBi\nSncjCyOEBpenNiYomgSWxKW0F? NF3uUoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK1OFQ5PCd-MkiyOVQ1QDR:L3G+
BMD NFvNNmFHfW6ldHnvckBie3OjeR?= MV2xJJVO M2f0c|Q5KGi{cx?= MlvTTY5lfWO2aX;uJI9nKFSOUkegdoVk\XC2b4KtcYVlcWG2ZXSgR|U4SkxxNjDtc5V{\SCETVSgZ4VtdHNiYXP0bZZifGmxbjDhd5Nme3OnZDDhd{B2eHKnZ4XsZZRqd25ib3[gR2Q5PiCjdDCxJJVOKGGodHXyJFQ5KGi{czDifUBndG:5IHP5eI9u\XS{eR?= MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ7OUGyOkc,OTl{OUmxNlY9N2F-
BMD MoHXSpVv[3Srb36gZZN{[Xl? M2HxUVEhfU1? NVywc4pJPDhiaILz MWLJcoR2[3Srb36gc4YhXEyUNzDy[YNmeHSxcj3t[YRq[XSnZDDDOVdDVC94IH3veZNmKEKPRDDj[YxteyCjY4TpeoF1cW:wIHHzd4V{e2WmIHHzJJVxemWpdXzheIlwdiCxZjDNTGMh[2yjc4OtNkBifCBzIIXNJIFnfGW{IES4JIhzeyCkeTDmcI94KGO7dH;t[ZRzgQ>? M1P4[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7Mkm5NVI3Lz5zOUK5PVEzPjxxYU6=
BMD NXHPfZZ3TnWwY4Tpc44h[XO|YYm= MojGNUB2VQ>? MWW0PEBpenN? MXTJcoR2[3Srb36gc4YhXEyUNzDy[YNmeHSxcj3t[YRq[XSnZDDDOVdDVC94IH3veZNmKEKPRDDj[YxteyCjY4TpeoF1cW:wIHHzd4V{e2WmIHHzJJVxemWpdXzheIlwdiCxZjDDSFQxKGG2IEGgeW0h[W[2ZYKgOFghcHK|IHL5JIZtd3diY4n0c41mfHK7 NXjPT4E1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyPVkyOjZpPkG5Nlk6OTJ4PD;hQi=>
BMD NIrBNlZHfW6ldHnvckBie3OjeR?= M2Wye|UhfU1? NUi5doc2OjRiaILz NHz4SWJKdmS3Y4Tpc44hd2ZiVFzSO{Bz\WOncITvdk1u\WSrYYTl[EBEPTeETD:2JI1wfXOnIFLNSEBk\WyuczDhZ5RqfmG2aX;uJIF{e2W|c3XkJIF{KEmOMUKgdJJw\HWldHnvckBifCB3IIXNJIFnfGW{IEK0JIhzeyCkeTDFUGlUSQ>? M1f2eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7Mkm5NVI3Lz5zOUK5PVEzPjxxYU6=

... Click to View More Cell Line Experimental Data

体内研究 在野生型小鼠中,Resiquimod (50 nmol, i.p.)诱导IFN-α,TNF-α和IL-12的血清浓度增加,而TLR7-缺失或MyD88-缺失的小鼠不会增加其细胞因子。[1]在过敏性哮喘小鼠模型中,Resiquimod (i.n., 20 μg/小鼠)通过减少Nrf2信号从而减少过敏原诱导的气道反应和炎症。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验:

[1]

- 合并
  • Animal Models: Wild-type mice, TLR7-deficient mice, and MyD88-deficient mice
  • Dosages: 50 nmol
  • Administration: i.p.
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 63 mg/mL (200.39 mM)
Water Insoluble
Ethanol '''''21 mg/mL warmed

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 314.38
化学式

C17H22N4O2

CAS号 144875-48-9
储存条件 粉状
溶于溶剂
别名 S28463

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04127864 Active not recruiting Procedure: Colorectal cancer surgery Colorectal Cancer|Surgery University of Copenhagen|Zealand University Hospital October 14 2019 --
NCT02688478 Unknown status Other: Phthalate|Other: Filtered Air|Other: Allergen Allergies University of British Columbia February 2 2017 Not Applicable
NCT00960752 Completed Drug: gp100|Drug: R848 gel|Drug: MAGE-3 Melanoma M.D. Anderson Cancer Center May 20 2010 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
免费分装抑制剂
Tags: 购买Resiquimod (R-848) | Resiquimod (R-848)供应商 | 采购Resiquimod (R-848) | Resiquimod (R-848)价格 | Resiquimod (R-848)生产 | 订购Resiquimod (R-848) | Resiquimod (R-848)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID